Issue 67, 2018

Matrix metalloproteinase targeted peptide vesicles for delivering anticancer drugs

Abstract

A matrix metalloproteinase (MMP) targeted tetrapeptide vesicle has been designed and developed, which strongly binds at a MMP9 enzymatic site. Interestingly, it has a propensity to encapsulate and deliver the doxorubicin drug specifically to the cancer cell, induces superior apoptotic death, and inhibits the metastatic cancer cell migration and growth of multicellular 3D spheroids.

Graphical abstract: Matrix metalloproteinase targeted peptide vesicles for delivering anticancer drugs

Supplementary files

Article information

Article type
Communication
Submitted
13 Jul 2018
Accepted
24 Jul 2018
First published
24 Jul 2018

Chem. Commun., 2018,54, 9309-9312

Matrix metalloproteinase targeted peptide vesicles for delivering anticancer drugs

D. Bhunia, K. Pradhan, G. Das, S. Ghosh, P. Mondal and S. Ghosh, Chem. Commun., 2018, 54, 9309 DOI: 10.1039/C8CC05687K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements